420Patients.com is accepting qualified medical marijuana patients and caregivers to join our network. We value every registered member and we hope to serve you in Arizona. This article brought to you by 420 community friends mmjbusinessdaily.com
A Florida biopharmaceutical company said it has been awarded the first U.S. patent for the commercial development of synthetic cannabis-based medical treatments.
Tampa-based Teewinot Life Sciences, formerly known as CBC Biotechnologies, said in a news release the patent – U.S. Patent No. 9,359,625 – claims a biosynthetic process for manufacturing the cannabinoids THCA, CBDA and CBCA.
The company said its synthetic production method is faster than plant cultivation, does less environmental damage, and results in a purer cannabinoids.
“Our use of synthetic biology represents a significant advancement from current plant extraction and chemical synthesis methods,” Jeff Korentur, Teewinot’s CEO,